Biohit’s ColonView validation for colorectal cancer screening program in Brazil
Biohit Oyj Press Release December 20, 2013 at 15:15 local time (EET)
Barretos Cancer Hospital (BCH) in Brazil starts a clinical study validating Biohit’s ColonView compared as one of the two potential alternatives for the colorectal cancer (CRC) screening program decided to start at BCH in 2015. In contrast to the comparison test, ColonView is rapid test specific for detecting human blood in the stools, derived from CRC and its precursors. Validation of the test in a clinical setting is the necessary first step before consideration for inclusion in a population-based screening program.
Barretos Cancer Hospital is one of the leading cancer hospitals in Brazil, with extensive international network of cancer research institutions in USA, Europe and Latin America.
Chief Medical Director of Biohit Oyj, MD, PhD, Professor Kari Syrjänen: “This is an important and necessary first step in the way towards possible incorporation of ColonView test in a population-based CRC screening program in this country where colorectal cancer is an increasing public health problem.”
Attachment:
Suomalainen FIT-testi: Entistä tehokkaampaa suolistosyövän seulontaa (PDF) (in Finnish)
Available online: http://www.swiflet.com/bpfionko/oncology/6/1/
Additional information:
Chief Medical Director of Biohit Oyj, MD, PhD, Professor Kari Syrjänen
tel. +358 9 773 861
kari.syrjanen@biohit.fi
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com